https://www.selleckchem.com/GSK-3.html
1%). The pooled prevalence of CD in AIH was 3.5% (95% CI=1.6%-5.3%) (heterogeneity P=.874; I =0.0%), which is clearly higher than the 1% CD seen in most general populations. When also including studies where CD had been diagnosed through positive serology without biopsy (15 studies n=1817 individuals with AIH), the pooled prevalence of CD was 2.9% (95% CI=2.1%-3.8%) (heterogeneity P.001; I =66.8%). Our results demonstrate a higher prevalence of CD in individuals with AIH compared to the general population. CD screening may be considered in pat